Actively Recruiting
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
Led by National Cancer Center, Korea · Updated on 2026-02-13
520
Participants Needed
10
Research Sites
395 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
CONDITIONS
Official Title
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and written informed consent
- Age 18 to under 80 years
- Histologically confirmed FIGO stage III-IV primary epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Treated with three cycles of neoadjuvant chemotherapy
- Underwent interval complete cytoreduction or cytoreduction with residual disease no deeper than 2.5 mm
- Life expectancy greater than 3 months as judged clinically
- Adequate organ function for surgery and HIPEC
- Women medically unable to conceive or of childbearing potential agree to contraceptive guidelines during treatment
- Consent to provide clinical information for secondary use if desired
You will not qualify if you...
- Diagnosis of non-epithelial ovarian carcinoma or borderline ovarian tumor
- No neoadjuvant chemotherapy received
- Interval cytoreduction with residual disease deeper than 2.5 mm
- Life expectancy 3 months or less as judged clinically
- History of previous malignancy within 5 years affecting treatment results, except certain skin cancers and early endometrial carcinoma
- Presence of myelodysplastic syndrome or acute myeloid leukemia
- Active central nervous system metastasis or unstable brain metastases
- Active infections requiring systemic antibiotic treatment
- Uncontrolled active tuberculosis
- Psychiatric or substance abuse disorders interfering with trial participation
- Hypersensitivity or contraindications to cisplatin
- History of allogeneic tissue or organ transplantation or double umbilical cord transplantation
- Any condition or therapy that may interfere with study results or participation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Chungnam National University Hospital
Sejong, Chungcheongnam-do, South Korea
Not Yet Recruiting
2
Chungnam National University Sejong Hospital
Sejong, Chungcheongnam-do, South Korea
Not Yet Recruiting
3
Ilsan CHA University Hospital
Goyang-si, Gyeonggi-do, South Korea
Actively Recruiting
4
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Actively Recruiting
5
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Actively Recruiting
6
Pusan National University Hospital
Pusan, South Korea
Not Yet Recruiting
7
Pusan National University Yangsan Hospital
Pusan, South Korea
Not Yet Recruiting
8
Asan Medical Center
Seoul, South Korea
Not Yet Recruiting
9
Ewha Womans University Mokdong Hospital
Seoul, South Korea
Not Yet Recruiting
10
Severance Hospital
Seoul, South Korea
Actively Recruiting
Research Team
M
Myong Cheol Lim, MD, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here